TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or PO
Study: NCT00046930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zosuquidar trihydrochloride
Description: Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored.
Study: NCT00596141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OroScience Topical Oral Wound Emulsion
Description: TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
Study: NCT03632603

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention during study period.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: No intervention during study period.
Study: NCT02060032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.2% Atorvastatin local drug delivery

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 1.2% simvastatin local drug delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo local drug delivery
Study: NCT04326660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCOPE-Chinese Women
Description: SCOPE-Chinese Women is a smart-phone based intervention that includes a Fitbit tracking device to monitor daily activity, 12-weeks of educational modules delivered by WeChat, and Bi-weekly messages that encourage positive behavioral change. The data will be examined by the research team to assess efficacy of the intervention.
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO
Study: NCT00460590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: ID vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: ID vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA 85A
Description: ID vaccine
Study: NCT02151331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Facilitation
Description: Non-responding sites randomized to receive external facilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External + Internal Facilitation
Description: Non-responding sites randomized to receive both internal and external facilitation
Study: NCT01459991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut
Description: Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MyPyramid
Description: Participants will follow a USDA MyPyramid style diet for lactating moms.
Study: NCT01519674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
Study: NCT03294395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate, Injectable
Description: single dose 5mg/kg (maximum 400mg) intramuscular injection
Study: NCT01519674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Subjects will continue on their pre-trial sitagliptin treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Subjects will continue on their pre-trial sitagliptin treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Subjects will continue on their pre-trial metformin treatment.
Study: NCT04738591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABE-TEXT
Description: Participants will receive daily (from monday to friday) text messages in their mobile phones during three months.
Study: NCT01610596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halobetasol Propionate Lotion 0.05%
Description: Apply twice daily for 1-2 weeks, not to exceed 50 grams per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00090415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive behavioral therapy
Description: Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nelarabine
Description: Given IV
Study: NCT03294395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: single dose 500mg intramuscular injection
Study: NCT01005914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
Study: NCT01931878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
Study: NCT03190811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 plus DC-CIK
Description: Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 alone
Description: Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
Study: NCT01675648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Lofexidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Diazepam
Study: NCT02285088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GBT440
Description: GBT440 will be administered as oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as oral capsules
Study: NCT01028482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: psychotherapy
Description: psychotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapy
Description: psychotherapy
Study: NCT00663026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: 5 mg bapineuzumab subcutaneous injection once per week for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: 10 mg bapineuzumab subcutaneous injection once per week for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo subcutaneous injection once per week for 6 months
Study: NCT03685422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Visual analog scale-anxiety (VAS-A), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
Study: NCT03794050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training exercise
Description: randomized complete crossover for acute resistance training exercise session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training exercise
Description: randomized complete crossover for acute aerobic exercise training exercise session
Study: NCT02939625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continue Positive Airway Pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continue Positive Airway Pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continue Positive Airway Pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilevel positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilevel positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilevel positive airway pressure
Study: NCT03151304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: 45 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: SC or IV injection
Study: NCT00515918

Intervention type: DIETARY_SUPPLEMENT
Intervention: iron
Study: NCT04411914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic Acid
Description: Drug will be given in 250mg capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00426439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (Coartem)
Description: Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (Coartem)
Description: Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
Study: NCT04402840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
Study: NCT04671121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart pressure pneumoperitoneum
Description: CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low pressure pneumoperitoneum
Description: CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
Study: NCT01256502

Intervention type: DEVICE
Group type: OTHER
Intervention: SERI® Surgical Scaffold
Description: Breast reconstruction surgery
Study: NCT04004416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo and fMRI
Description: A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo and fMRI
Description: A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and fMRI
Description: A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (vitals, qols) and optional blood draw prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
Study: NCT01005914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
Study: NCT00979199

Intervention type: OTHER
Group type: OTHER
Intervention: Non invasive cardiac imaging
Description: Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
Study: NCT00706485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Plaque Applicator
Description: Placed on the dura during surgery for 10-17 1/2 minutes
Study: NCT04082338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VPN
Description: The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TM
Description: Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TM
Description: Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
Study: NCT01609023

Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
Study: NCT04220970

Intervention type: OTHER
Intervention: BIA-ALCL
Description: Observational : no intervention
Study: NCT01005914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Day 1-4; 11-14: 40 mg daily
Study: NCT02673814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab
Study: NCT00792961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscopy
Description: Rigid drop-in endomicroscope imaging probe
Study: NCT02068703

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Presentation
Description: Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education Presentation
Description: Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Tool Demonstration
Description: Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
Study: NCT00171951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 600 μg or 900 μg was administered as an SC injection.
Study: NCT00352417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: 100 mg, oral dosing, 1 time daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dosing, 1 time daily for 12 weeks
Study: NCT00661895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril and Hydrochlorothiazide
Description: L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril and Hydrochlorothiazide
Description: L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine XL
Description: 30 mg extended release tablets, 60 mg extended release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine XL
Description: 30 mg extended release tablets, 60 mg extended release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol tartrate
Description: 50 mg tablets \& 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Description: 50 mg tablets \& 100 mg tablets
Study: NCT01005914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Day 4: 50 mg/m2 IV over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 600 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion